tegavivint
iterion therapeutics
['bc2059', 'tegavivint']
dr. lee cranmer is presenting "results of a phase i dose escalation and expansion study of tegavivint (bc2059), a first-in-class tbl1 inhibitor for patients with progressive, unresectable desmoid tumor" at #asco22. sunday, june 5, 11:30 a.m. cdt 
Fred Hutch is pushing cancer and disease research forward — because every discovery is another step toward better, longer lives. #CuresStartHere